Value of a concomitant functional endoscopic paranasal sinus surgery in CRSwNP patients with partial response under antibody therapy.

Introduction Biologicals, which have been available since 2019 for the treatment of CRSwNP patients with severe disease, fortunately lead to a significant improvement in symptoms and quality of life in the majority of patients – with a limited side effect profile at the same time. Some patients, however, show a stagnant manifestation of symptoms with continued relevant complaints and persistent nasal polyps after an initial moderate improvement during this therapy. This group of patients could benefit from functional endoscopic sinus surgery (FESS) with continuation of antibody therapy to maintain the postoperative condition.